Ongoing research continues to explore the potential of these antagonists in various clinical applications, offering new avenues for treatment and a deeper understanding of GLP-1's role in human health
doi: 10.1371/journal.pone.0001709 157 RozhdestvenskyTSRobeckTGalivetiCRRaabeCASeegerBWoltersAet al
However, from a pricing and product management standpoint, insurers may also want to consider behavioral responses and contract dynamics
Editor's note: This text-based course is a transcript of the webinar, GLP-1s and More: Pharmacology for Diabetes Mellitus and Other Endocrine Conditions, presented by Melissa Bednarek, PT, DPT, PhD, CCS
GLP-1 users who maintain at least 80 percent adherence to therapy see greater cost reductions, and statistically significant decreases in MACE hospitalizations and condition incidence than those with lower adherence